Corcept Therapeutics
CORT
215 hedge funds and large institutions have $1.38B invested in Corcept Therapeutics in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 78 increasing their positions, 75 reducing their positions, and 23 closing their positions.
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
1% more funds holding
Funds holding: 212 → 215 (+3)
4% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 75
0.53% less ownership
Funds ownership: 76.55% → 76.01% (-0.53%)
5% less capital invested
Capital invested by funds: $1.45B → $1.38B (-$69.3M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
67% less call options, than puts
Call options by funds: $8.13M | Put options by funds: $25M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.4M |
| 2 |
BlackRock
New York
|
+$22.5M |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
+$8.69M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$7.63M |
| 5 |
KBC Group
Brussels,
Belgium
|
+$6.42M |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$13.3M |
| 2 |
NC
Nexthera Capital
New York
|
-$12.4M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$9.74M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$9.19M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$9.01M |
CORT Hedge Fund Activity: Q2 2018 in Review
215 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2018, worth a combined $1.38B — down 4.8% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CORT positions and 23 closed out — a net gain of 4 holders — while 78 added to existing stakes and 75 trimmed.
The largest buyer was Vanguard Group, adding an estimated $27.4M. The largest seller was Federated Hermes, cutting an estimated $13.3M.
- 215 institutional investors held Corcept Therapeutics (CORT) as of Q2 2018, up from 212 in Q1 2018.
- Funds reported $1.38B of Corcept Therapeutics stock for Q2 2018, down 4.8% quarter-over-quarter.
- 27 funds opened new Corcept Therapeutics positions in Q2 2018 and 23 closed out, a net change of +4 holders.
- The largest Corcept Therapeutics buyer in Q2 2018 was Vanguard Group, an estimated $27.4M added.
- The largest Corcept Therapeutics seller in Q2 2018 was Federated Hermes, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2018.